Stelios Papadopoulos - 03 Mar 2025 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Reporting relationship: Director
Issuer ticker: OVID
Reported as of: 03 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2025, 16:44:34 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 30 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason Minio, Attorney-in-Fact

Key filing fact

Stelios Papadopoulos filed Form 4 for Ovid Therapeutics Inc. (OVID) on 04 Mar 2025.

Key facts

This page summarizes Stelios Papadopoulos's Form 4 filing for Ovid Therapeutics Inc. (OVID).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2025, 16:44.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OVID transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 03 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $0.4900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the stock option will vest in 36 equal monthly installments commencing on April 3, 2025, subject to the Reporting Person's continued services through each such date.